Furthermore, preclinical data indicates that the radiosensitizing effects of PARP inhibitors such as OLA are dose-dependent [26] and thus it would likely be beneficial to expose tumor cells to higher concentrations of OLA than can be achieved by systemic treatment. The gene discussed is PARP1; the disease is neoplasm.